Quick Answer
Alaunos Therapeutics, Inc. reported Stockholders Equity of $2.15 million for fiscal year 2025.
Alaunos Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $2.15M | +4.4% |
| 2024 | $2.06M | -67.3% |
| 2023 | $6.31M | -83.6% |
| 2022 | $38.55M | -33.6% |
| 2021 | $58.06M | -53.2% |
| 2020 | $123.98M | +30.5% |
| 2019 | $95.01M | +11.0% |
| 2018 | $85.56M | +188.4% |
| 2017 | -$96.81M | -25.2% |
| 2016 | -$77.30M | -188.5% |
| 2015 | $87.37M | +158.2% |
| 2014 | $33.84M | -31.5% |
| 2013 | $49.38M | +1.9% |
| 2012 | $48.45M | -32.3% |
| 2011 | $71.61M | +134.4% |
| 2010 | $30.55M | +8.7% |
| 2009 | $28.10M | +317.0% |
| 2008 | $6.74M | -77.8% |
| 2007 | $30.37M | +14.5% |
| 2006 | $26.53M | +268.4% |
| 2005 | $7.20M | +5101.4% |
| 2004 | -$144.0K | -142.4% |
| 2003 | $340.0K | -32.0% |
| 2003 | $500.0K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.80M | +2.9% | -23.4% |
| June 30, 2025 | $3.66M | -2.9% | +246.0% |
| March 31, 2025 | $1.06M | -77.9% | -48.7% |
| December 31, 2024 | $2.06M | -67.3% | -24.3% |
| September 30, 2024 | $2.72M | -80.4% | -27.8% |
| June 30, 2024 | $3.77M | -82.6% | -21.4% |
| March 31, 2024 | $4.80M | -83.7% | -23.9% |
| December 31, 2023 | $6.31M | -83.6% | -54.6% |
- Alaunos Therapeutics, Inc. showed an increase of +4.4% in Stockholders Equity compared to the prior fiscal year.
- Over the 2003–2025 period, Alaunos Therapeutics, Inc.’s stockholders equity has grown by 330.6% (from $500.0 thousand to $2.15 million).
- The most recent figure is from Alaunos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: